Drug maker Aurobindo Pharma today said it has received final approval from the US health regulator for Venlafaxine Hydrochloride tablets, used as an anti-depressant.
The company has received the final approval from the US Food & Drug Administration (USFDA) for Venlafaxine Hydrochloride tablets, Aurobindo Pharma said in a filing to the Bombay Stock Exchange (BSE).
The tablets will be launched shortly in strengths of 25 mg, 37.5 mg, 75 mg and 100 mg, the filing added.
Venlafaxine Hydrochloride tablets are used in the treatment of major depressive disorders.
Aurobindo has a total of 114 Abbreviated New Drug Application (ANDA) approvals from the USFDA.
Shares of Aurobindo Pharma today closed at Rs 948.90 on the BSE, down 0.13 per cent from previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app